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Purpose: We investigated the effect of total intravenous anesthesia (TIVA) with 
propofol on postoperative nausea and vomiting (PONV) after robot-assisted lapa-
roscopic radical prostatectomy (RLRP) in patients at low risk of developing 
PONV, in comparison to balanced anesthesia with desflurane. Materials and 
Methods: Sixty two patients were randomly assigned to the Des or TIVA group. 
Propofol and remifentanil were used for induction of anesthesia in both groups 
and for maintenance of the anesthesia in the TIVA group. In the Des group, anes-
thesia was maintained with desflurane and remifentanil. In both groups, postopera-
tive pain was controlled using fentanyl-based intravenous patient controlled anal-
gesia, and ramosetron 0.3 mg was administered at the end of surgery. The 
incidence of PONV, severity of nausea and pain, and requirements of rescue anti-
emetics and analgesics were recorded. Results: The incidence of nausea in the 
post-anesthetic care unit was 22.6% in the Des group and 6.5% in the TIVA 
(p=0.001) group. The incidence of nausea at postoperative 1-6 hours was 54.8% in 
the Des group and 16.1% in the TIVA group (p=0.001). At postoperative 6-48 
hours, there were no significant differences in the incidence of nausea between 
groups. Conclusion: In order to prevent PONV after RLRP in the early postopera-
tive period, anesthesia using TIVA with propofol is required regardless of patient-
related risk factors.
Key Words:   Postoperative nausea and vomiting, propofol, laparoscopic surgery, 
prostatectomy
INTRODUCTION
Robot-assisted laparoscopic radical prostatectomy (RLRP) has gained popularity 
since it was first introduced in 2001, and is widely replacing conventional open 
prostatectomy. RLRP entails benefits of reduced blood loss, nerve sparing, less 
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ican Society of Anesthesiologists physical status of I or II, 
ranging in age from 50 to 70 years, were enrolled. To con-
trol the anticipated risk for PONV, we excluded patients 
with a history of motion sickness or PONV, antiemetic use 
within 24 hours before surgery, regular corticosteroid use, 
chemotherapy within 4 weeks or radiotherapy within 8 
weeks, hepatic dysfunction, confirmed renal impairment, or 
obesity (body mass index >35 kg/m2). Patients were ran-
domly allocated to either the balanced anesthesia (Des 
group) or TIVA (TIVA group) group by means of random 
numbers generated by a computer. Antiemetic prophylaxis 
was commonly administered in both groups. A physician of 
the anesthesiology preoperative evaluation clinic who was 
not involved in the current trial performed randomization 
and assignment.  
All patients were premedicated intravenously with mid-
azolam 0.05 mg/kg and glycopyrrolate 0.2 mg at 1 hour 
and just before the induction of anesthesia, respectively. 
Standard monitoring devices were applied. In the TIVA 
group, propofol and remifentanil were concurrently infused 
using a target controlled infusion (TCI) system for induc-
tion and maintenance of anesthesia. Effect site concentra-
tion was controlled using the Marsh, et al.16 and Minto, et 
al.17 models for propofol and remifentanil, respectively. Af-
ter the loss of consciousness, intravenous rocuronium 0.6 
mg/kg was administered for relaxation. After tracheal intu-
bation, a 20-G radial artery catheter was inserted for contin-
uous blood pressure monitoring. The effect site concentra-
tions of propofol and remifentanil were kept within the 
ranges of 2-5 mcg/mL and 2-5 ng/mL, respectively. In the 
Des group, anesthesia was induced with propofol bolus (1.5 
mg/kg) and remifentanil, and maintained with desflurane 
and remifentanil. Like the TIVA group, remifentanil was in-
fused using a TCI system. The end-tidal concentration of 
desflurane and the effect site concentrations of remifentanil 
were kept within the ranges of 4-7% and 2-5 ng/mL, re-
spectively. During the surgery, the concentrations of propo-
fol, desflurane, and remifentanil were titrated to maintain 
an arterial blood pressure and heart rate within 20% of 
baseline values. The depth of anesthesia was monitored us-
ing a bispectral index score monitor (A-200 bispectral in-
dex score monitor, Aspect Medical System Inc., Newton, 
MA, USA) within the range of 40-60. Controlled ventila-
tion was performed with 40% oxygen in air to maintain end-
tidal CO2 at 35-40 mm Hg during the surgery. Body temper-
ature was controlled to within 36-37°C using a forced air 
warming system throughout the surgery. During the opera-
postoperative pain, and shorter hospital stay.1,2 For optimal 
surgical exposure, RLRP usually requires a steep Tren-
delenburg position and prolonged intraperitoneal carbon di-
oxide (CO2) insufflations, resulting in increased intraab-
dominal pressure.3 CO2 insufflations during laparoscopic 
surgery, which causes peritoneal stretching and irritation, is 
known to play an important role in postoperative nausea 
and vomiting (PONV).4 If temporally extended, the pneu-
moperitoneum can also increase the risk for PONV.4 PONV 
causes patient discomfort and can lead to prolonged stay in 
the post-anesthesia care unit (PACU). Patients with PONV 
are also predisposed to complications of dehydration, elec-
trolyte imbalance, aspiration pneumonia, increased wound 
dehiscence, delayed recovery, prolonged hospital stay, and 
increased medical cost.5-8 Accordingly, anesthesiologists 
should give attention to preventing PONV in patients un-
dergoing RLRP, because the RLRP itself can be an impor-
tant risk factor for PONV, although most  patients involve 
fewer patient-related risk factors.5,9
Previous clinical studies suggested that total intravenous 
anesthesia (TIVA) with propofol significantly reduced PONV 
when compared to inhalation anesthetics.10,11 Furthermore, 
several studies recommended TIVA with propofol for anes-
thesia in patients at high risk for PONV.12-15 However, no 
studies were designed to evaluate the incidence and severi-
ty of PONV in patients undergoing RLRP at low risk for 
PONV. 
We designed a prospective single-site, double-blinded, 
randomized, and parallel-arm controlled trial to investigate 
the effects of TIVA with propofol on PONV in patients un-
dergoing RLRP in comparison to balanced anesthesia with 
desflurane. The primary endpoint was to compare the inci-
dence and severity of PONV for 48 hours postoperatively.
MATERIALS AND METHODS
　　　
This trial was conducted at Yonsei University College of 
Medicine, Seoul, Korea, between November 2010 and May 
2011. In addition to gaining the approval of the Institutional 
Review Board of Yonsei University College of Medicine (4-
2010-0361) and registration with clinicaltrial.gov (Unique 
Identifier: NCT01402622), this study was performed in full 
compliance with the Declaration of Helsinki. All partici-
pants were recruited from the anesthesiology preoperative 
evaluation clinic and provided written informed consent. 
Sixty two male patients scheduled for RLRP, with an Amer-
TIVA and PONV after RLRP
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RESULTS
 
RLRP was performed as planned in all patients and com-
plete data sets from the 62 patients were analyzed without 
any missing data.
Patients’ characteristics were similar between the two 
groups (Table 1). Preoperative and intraoperative variables 
associated with PONV, including Apfel score,9 anesthesia 
time, operating time, and fluid balances, were similar be-
tween the two groups (Table 2).
Because no significant differences were found between 
the groups after 6 hours postoperatively, data on postopera-
tive nausea and vomiting were presented for three time pe-
riods (PACU, 1-6 hours, and 6-48 hours) to discriminate 
immediate, early and late postoperative incidences (Table 
3). The overall incidence of nausea during the first 48 hours 
postoperatively was significantly lower in the TIVA group 
compared to the Des group (p=0.004). The incidences of 
nausea during PACU stay and at postoperative 1-6 hours 
tion, CO2 pneumoperitoneum was induced to maintain an 
intraabdominal pressure of 15±5 mm Hg using the Da Vin-
ci Robot Surgical System (Intuitive Surgical, Sunnyvale, 
CA, USA) in a 30° Trendelenburg position. All patients re-
ceived ramosetron 0.3 mg intravenously at 20 minutes be-
fore the end of the surgery. In both groups, postoperative 
pain was controlled using intravenous patient controlled an-
algesia (PCA), consisting of fentanyl 20 mcg/kg mixed 
with normal saline to comprise a total volume of 100 mL, 
administered at a basal rate of 2 mL/hour, with a bolus dose 
of 0.5 mL and a 15-minute lockout time. After extubation 
in a fully awake status, patients were transported to the 
PACU.
Nausea intensity was assessed using an 11-point verbal 
numerical rating scale (VNRS; 0-no nausea, 10-worst and 
intolerable nausea). The presence of nausea was defined as 
VNRS ≥1. The occurrence of PONV was defined as the 
presence of nausea, retching or vomiting. The severity of 
PONV was graded according to the VNRS and the pres-
ence of retching or vomiting (mild: 1-3, moderate: 4-6, se-
vere: 7-10 or with retching or vomiting). Postoperative pain 
was assessed using the visual analogue scale (VAS; 0-no 
pain, 100-worst and intolerable pain). An investigator who 
was blinded to the intraoperative management assessed the 
VNRS, VAS, and incidences of nausea, retching, or vomit-
ing at four time periods (during stay in PACU, and 1-6 
hours, 6-24 hours, and 24-48 hours postoperatively). Pa-
tients were asked to rate the VNRS of their most severe epi-
sode of nausea during each time period. Rescue antiemetic 
(ramosetron 0.3 mg) was administered intravenously for 
nausea >6 on VNRS and rescue analgesics (ketorolac 30 
mg) for pain >4 on VAS. 
Continuous variables were reported as means±SD. Di-
chotomous variables were presented as number of patients 
(percent). Between-group comparisons of continuous vari-
ables were performed by Student’s t-test or Mann-Whitney 
U test, as appropriate. Dichotomous variables were com-
pared using the chi-square or Fisher’s exact test. In a pre-
liminary study, 70% of patients had postoperative nausea 
after RLRP using the same anesthetic method as the Des 
group. A power estimation analysis of the preliminary study 
suggested that 31 patients per group would be required to 
obtain a power of 80%, considering a type I error of 0.05, 
and expecting a reduction from 70% to 35% in the inci-
dence of postoperative nausea. All statistical analyses were 
performed using SPSS software version 18.0 (SPSS Inc., 
Chicago, IL, USA). 
Table 1. Patient Characteristics
Des (n=31) TIVA (n=31)
Age (yrs)   61.6±5.7   62.4±5.3
Height (cm) 167.6±3.7 166.1±6.1
Weight (kg)     71.7±11.6   68.5±6.2
ASA class II 16 (51.6) 14 (45.2)
Diabetes mellitus 2 (6.5) 3 (9.7)
Hypertension 14 (45.2) 11 (35.5)
ASA, American Society of Anesthesiologists; Des, patients receiving bal-
anced anesthesia; TIVA, patients receiving total intravenous anesthesia; 
SD, standard deviation. 
Values are presented as mean±SD or number of patients (%).
Table 2. Preoperative and Intraoperative Variables Affecting 
the Incidence of PONV
Des (n=31) TIVA (n=31)
Non-smoking 21 (67.7) 23 (74.2)
Apfel score9   1.7±0.5   1.7±0.4
Anesthesia time, min 188.6±35.5 191.9±38.5
Operating time, min 147.1±36.8 147.2±31.2
Input
    Crystalloid 1555.2±515.0 1651.7±696.9
    Colloid   237.9±306.3   175.9±224.7
Output
    Urine   190.0±220.3   195.5±151.0
    Bleeding   420.7±403.7   389.7±386.0
PONV, postoperative nausea and vomiting; Des, patients receiving bal-
anced anesthesia; TIVA, patients receiving total intravenous anesthesia; 
SD, standard deviation. 
Values are presented as mean±SD or number of patients (%). 
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48 hours postoperatively was significantly lower in the TIVA 
group [2 (6.5%)] compared to the Des group [10 (32.3%), 
p=0.01], especially in the PACU [0 (0%) vs. 6 (19.4%), p= 
0.01) and at postoperative 1-6 hours [0 (0%) vs. 8 (25.8%), 
0.002] (Fig. 1).
Pain intensity and the number of patients who required 
rescue analgesics were comparable between the two groups 
(Table 4).
DISCUSSION
In this prospective, double-blinded, randomized, and parallel-
arm controlled trial, TIVA with propofol reduced not only the 
were significantly lower in the TIVA group, compared to 
the Des group (p=0.023 and 0.001, respectively), but not 
significantly different at 6-48 hours postoperatively.
VNRS at PACU and 1-6 hours postoperatively was sig-
nificantly lower in the TIVA group compared to the Des 
group (p=0.043 and 0.001, respectively). VNRS at 6-48 
hours postoperatively were not significantly different be-
tween the two groups. In the Des group, retching developed 
in 4 and 6 patients, vomiting was reported in 1 and 3 pa-
tients, and rescue antiemetic drug was administrated in 4 
and 8 patients at the PACU and postoperative 1-6 hours, re-
spectively. However, none of the patients in the TIVA 
group demonstrated retching, vomiting, or rescue antiemet-
ic requirement during the same periods (Table 3). 
The incidence of moderate to severe PONV during the first 
Table 3. Postoperative Nausea and Vomiting Associated 
Variables
Des (n=31) TIVA (n=31)
Patients with presence of nausea 
    PACU   7 (22.6) 1 (3.2)*
    1-6 hrs 17 (54.8) 5 (16.1)*
    6-48 hrs   6 (19.4) 5 (16.1)
    Total 18 (58.1) 7 (22.6)*
VNRS 
    PACU 0.9±1.7 0.2±0.7*
    1-6 hrs 2.1±2.4 0.4±0.8*
    6-48 hrs    1±2.3 0.5±1.1
Patients with retching 
    PACU   4 (12.9) 0 (0)*
    1-6 hrs   6 (19.4) 0 (0)*
    6-48 hrs   3 (9.7) 2 (6.5)
    Total   7 (22.6) 2 (6.5)
Patients with vomiting
    PACU   1 (3.2) 0 (0)
    1-6 hrs   3 (9.7) 0 (0)
    6-48 hrs   1 (3.2) 1 (3.2)
    Total   4 (12.9) 1 (3.2)
Patients with rescue antiemetics
    PACU   4 (12.9) 0 (0)*
    1-6 hrs   8 (25.8) 0 (0)*
    6-48 hrs   2 (6.5) 2 (6.5)
    Total   7 (22.6) 2 (6.5)
PACU, post anesthetic care unit; total, during 48 hours after the operation; 
VNRS, verbal numerical rating scale; Des, patients receiving balanced 
anesthesia; TIVA, patients receiving total intravenous anesthesia; SD, 
standard deviation.
Values are presented as mean±SD or number of patients (%). 
*p<0.05 vs. Des group.
Table 4. Postoperative Pain Associated Variables 
Des (n=31) TIVA (n=31)
VAS
    PACU 42.9±17.1   41.9±18.3
    1-6 hrs 42.5±18.3   40.3±15.4
    6-24 hrs 33.5±14.5   34.5±11.5
    24-48 hrs 22.2±10.8 21.3±9.2
Patients with rescue analgesics
    PACU 12 (38.7) 12 (38.7)
    1-6 hrs   8 (25.8)   8 (25.8)
    6-24 hrs   5 (16.1) 3 (9.7)
    24-48 hrs 2 (6.5) 2 (6.5)
    Total 21 (67.7) 17 (54.8)
VAS, visual analogue scale; PACU, post anesthetic care unit; total, during 
48 hours after the operation; Des, patients receiving balanced anesthesia; 
TIVA, patients receiving total intravenous anesthesia; SD, standard devia-
tion. 
Values are presented as mean±SD or number of patients (%). 
*p<0.05 vs. Des group.
Fig. 1. The incidence of moderate to severe PONV during postoperative 48 
hours. PONV, postoperative nausea and vomiting; patients with moderate 
to severe PONV, patients with VNRS ≥4 or with retching or vomiting at ei-
ther time period; Des, patients receiving balanced anesthesia; TIVA, pa-
tients receiving total intravenous anesthesia; PACU, post anesthetic care 
unit; VNRS, verbal numerical rating scale. *p<0.05 vs. Des group.
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the TIVA group showed lower incidences of nausea, retch-
ing, and vomiting, and less VNRS at postoperative 6-48 
hours compared to the Des group, no significant difference 
was observed between the two anesthetic methods after 
postoperative 6 hours. Our results are in agreement with a 
recent study,29 in which TIVA with propofol was shown to 
exert a preventive effect on PONV at early postoperative 
periods (0-6 hours) compared to isoflurane. As the anti-
emetic effect of propofol was shown to be maintained fur-
ther beyond 2 hours postoperatively in both investigations, 
these results could provide evidence for the early antiemet-
ic effect of propofol. In contrast to Grundmann, et al.,30 
who reported no difference in the incidences of PONV be-
tween TIVA with propofol and desflurane/N2O in patients 
undergoing short surgical procedures after propofol bolus 
induction, the incidence of PONV was significantly lower 
in the TIVA group compared to the Des group in our study. 
Therefore, much longer use of propofol with TIVA might 
be effective in preventing PONV for a longer period than 
the use of propofol for induction only. 
Previous studies have recommended TIVA with propofol as 
the anesthetic method for patients at high risk for PONV.12,13,15 
Although patients in this study involved fewer patient-relat-
ed risk factors for PONV, the surgical method itself (RLRP) 
led to a higher incidence of PONV at the early postoperative 
period in the Des group, compared to the patients adminis-
tered TIVA with propofol. Moreover, TIVA with propofol 
was shown to reduce the severity of PONV at 6 hours post-
operatively. Therefore, anesthesia with TIVA along with pro-
pofol could be beneficial for preventing and mitigating 
PONV at early postoperative periods in patients undergoing 
RLRP. 
The limitation of this study is that VNRS was used to as-
sess the severity of nausea, which solely depends on the 
memory of the patients. Therefore, there might be bias in re-
gards to patient’s ability to recall the severity of their nausea 
symptoms.
In conclusion, in order to prevent PONV after RLRP in 
early postoperative periods, anesthesia using TIVA with 
propofol could suffice, regardless of patient-related risk 
factors.
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incidence, but also the severity of PONV when compared to 
balanced anesthesia with desflurane in patients at low risk 
of PONV immediately after RLRP.
The cause of PONV is not yet fully understood. Multiple 
factors, including patient-related factors, type of the surgi-
cal procedure, or choice of the anesthetics, are considered 
possible etiologies of PONV.12,13 Despite the fact that the 
patients in the Des group exhibited only one or no patient-
related risk factors for PONV and all received ramosetron 
as prophylaxis, the incidence of PONV was 58.1%, which 
is much higher than the incidence of 36% after laparoscop-
ic cholecystectomy.18 Although anesthetized with desflu-
rane and remifentanil, the higher incidence of PONV in the 
Des group in our study might be attributable to the surgery 
(RLRP). In laparoscopic surgery, prolonged pneumoperito-
neum is known to increase the risk of PONV by 60% of the 
baseline value for every 30 minutes of extended operating 
time.4,6,12 In this study, the mean operating time of RLRP 
was 147 min. This is much longer than the mean operating 
time of laparoscopic cholecystectomy, which was recently 
reported to be only 35 min.19 As RLRP usually requires 
prolonged intraperitoneal CO2 insufflations, resulting in 
high intraabdominal pressure, this may have contributed to 
the higher incidence of PONV in the Des group.
Propofol is known to exert an antiemetic effect even 
though the exact mechanism is still unclear. One study re-
ported that propofol reduces PONV by blocking the 5-hy-
droxy-tryptamin-3 receptor of the serotonergic system,20,21 
while others reported that inhibition of the chemoreceptor 
trigger zone and vagal nuclei, which are directly related to 
nausea and vomiting, is associated with the antiemetic ef-
fect of propofol.22 
Several studies showed that patients administered propo-
fol anesthesia had less PONV than those with other anes-
thetics.23-25 However, one suggested that propofol anesthe-
sia demonstrated superiority in preventing PONV only for 
the immediate postoperative period at the PACU.24 Tramèr, 
et al.26 also put the antiemetic effect of propofol in doubt, as 
propofol exhibited a clinically relevant effect on PONV 
only for short-term period. Some studies suggested that the 
pro-emetogenic effect of inhalation anesthetics must be 
considered as an important cause of early PONV within 2 
hours, and the antiemetic effect of propofol may originate 
from a lack of such an early emetogenic effect.27,28 In our 
study, we found that TIVA with propofol reduced the inci-
dence and severity of PONV at postoperative 0-6 hours, 
compared to balanced anesthesia with desflurane. Although 
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